<div id="readability-page-1"><p>Corient Private Wealth LLC boosted its stake in shares of  Moderna, Inc. (NASDAQ:MRNA - Free Report) by 155.8% during the second quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The fund owned 56,400 shares of the company's stock after acquiring an additional 34,354 shares during the quarter. Corient Private Wealth LLC's holdings in Moderna were worth $1,537,000 as of its most recent SEC filing.</p><ul><li>Moderna  Stock Looks Ripe for a Short Squeeze</li></ul><p>Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MRNA. Osaic Holdings Inc. increased its holdings in shares of  Moderna by 7.0% in the second quarter. Osaic Holdings Inc. now owns 46,709 shares of the company's stock valued at $1,289,000 after purchasing an additional 3,065 shares in the last quarter.  Thrivent Financial for Lutherans boosted its position in  Moderna by 600.7% in the 2nd quarter. Thrivent Financial for Lutherans now owns 92,999 shares of the company's stock valued at $2,566,000 after buying an additional 79,726 shares during the last quarter.  Marex Group plc acquired a new stake in shares of  Moderna in the 2nd quarter valued at $359,000.  State of Wyoming acquired a new stake in shares of  Moderna in the 2nd quarter valued at $94,000.  Finally, Hudson Bay Capital Management LP raised its position in shares of  Moderna by 108.4% during the second quarter. Hudson Bay Capital Management LP now owns 75,000 shares of the company's stock worth $2,069,000 after acquiring an additional 39,020 shares during the last quarter. Institutional investors and hedge funds own  75.33% of the company's stock. </p><h2>Moderna Stock Performance</h2><p>Shares of NASDAQ MRNA opened at $32.73 on Thursday. The stock has a market capitalization of $12.79 billion, a PE ratio of -4.06 and a beta of 1.11. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $48.92. The stock has a 50 day moving average price of $26.78 and a 200 day moving average price of $27.33. </p><ul><li>MarketBeat Week in Review – 03/10 - 03/14</li></ul><p>Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($2.15) by $1.64. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The business had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $893.29 million. During the same quarter last year, the company posted $0.03 earnings per share. Moderna's quarterly revenue was down 45.4% on a year-over-year basis.  As a group, research analysts forecast that  Moderna, Inc. will post -9.61 EPS for the current year. </p><h2>Insider Buying and Selling at Moderna</h2><p>In other news, Director Noubar Afeyan sold 23,853 shares of the stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $29.48, for a total value of $703,186.44. Following the completion of the transaction, the director owned 3,924 shares of the company's stock, valued at approximately $115,679.52. This represents a 85.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. 10.90% of the stock is currently owned by corporate insiders. </p><h2>Analysts Set New Price Targets</h2><ul><li>Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares</li></ul><p>Several research firms recently issued reports on MRNA. Weiss Ratings  reiterated a &#34;sell (e+)&#34; rating on shares of Moderna in a report on Wednesday, October 8th. Leerink Partners upped their target price on shares of Moderna from $15.00 to $18.00 and gave the company an &#34;underperform&#34; rating in a research report on Friday, November 21st. Citigroup lowered their price target on shares of Moderna from $30.00 to $28.00 and set a &#34;neutral&#34; rating for the company in a research report on Thursday, October 23rd. Morgan Stanley cut their price objective on shares of Moderna from $30.00 to $28.00 and set an &#34;equal weight&#34; rating on the stock in a report on Friday, December 12th. Finally, Needham &amp; Company LLC  reaffirmed a &#34;hold&#34; rating on shares of Moderna in a research note on Monday, October 20th. Two analysts have rated the stock with a Buy rating, twelve have assigned  a Hold rating and five have assigned  a Sell rating to the stock. Based on data from MarketBeat.com, the company  has a consensus rating of &#34;Reduce&#34; and an average target price of $29.21.</p><p><b>Get Our Latest Analysis on Moderna</b></p><h2>Moderna Company Profile</h2> (Free Report)<p>Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company's platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.  </p><p>Moderna's flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Moderna</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>Forget AI, This Will Be the Next Big Tech Breakthrough</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJOQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJOQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Moderna Right Now?</h2><p>Before you consider Moderna, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.</p><p>While Moderna currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MRNA

<p>Corient Private Wealth LLC increased its stake in Moderna, Inc. by 155.8% in Q2, owning 56,400 shares worth $1.54 million. Analysts have mixed ratings on Moderna, with a consensus rating of "Reduce" and an average target price of $29.21. Institutional investors own 75.33% of the stock, and recent insider transactions include a significant sale by Director Noubar Afeyan.</p>

Corient Private Wealth LLC Has $1.54 Million Stock Holdings in Moderna, Inc. $MRNA